PPT-Clinicians Perceptions and Practices of Urine Drug Testing in Buprenorphine Treatment

Isabel Lamont¹ Mariya Masyukova² Andrea Jakubowski ¹ Shadi Nahvi ¹ Tiffany Lu ¹ Teresa LopezCastro³ Yuting Deng ¹ ¹ Montefiore HospitalAlbert Einstein College of Medicine ² Project Renewal . Presented by:. Ben Johnson. Vice President. Fleet Screen, Ltd.. Identifying and responding to substance abuse: . Helps prevent the hiring of illegal substance abusers when pre-employment drug testing is required.. Ethical, Medical, and Legal Considerations. Bethany Medley, MSW. At 8 months pregnant, Jackie was receiving buprenorphine treatment for her diagnosed Opioid Use Disorder. Her buprenorphine provider requires urine drug screening at every visit. . Andrew Sonderman, MD. Prescription Drug Abuse. Newest . problem in the . field. Patients . believe . that they are “medications” and . do not . look at them as . drugs. Pharmaceutical companies make a fortune selling a “pill for every . Molly Rutherford, MD. Family Physician. Bluegrass Family Wellness. Crestwood, KY. I have no commercial interests to disclose. Learning Objectives. Review the ASAM decision making guidelines. Explain how to obtain a DEA waiver. Treatment (MAT):. Problem . or Solution?. Quintin Thomas Chipley, M.A., M.D., Ph.D.. a. nd. Greg Jones, M.D., ABFM, ABAM, MRO. Prepared for CAPTASA 2016. DISCLOSURES. Neither presenter has any financial interest in any mode of treatment as discussed in this presentation.. Some Best practices with medication assisted treatment Michele Flowers McCarthy, LPCC-S Director of Program Development Center for Behavioral Health Special thanks to Michele McCarthy Director of Program Development Advanced MAT Implementation: Compliance Testing and Addressing Recurring Opioid Use and Polysubstance Use Copyright 2019, University of Pittsburgh. All Rights Reserved. Julie Kmiec, DO Assistant Professor and Addition Psychiatrist and . M. edication . Assisted Treatment . and . Team . Training in . Rural . Colorado. Behavioral Health Provider Training. Module 3: . Pharmacology of Buprenorphine and Other Drugs. Copyright 2018 Regents of the University of Colorado.  All Rights Reserved. Diversion ControlDivisionDrug & Chemical Evaluation Section BUPRENORPHINETrade NameBuprenex®, Suboxone®, Subutex®December Introduction Buprenorphinewas rst marketed in the UnitedStates in 19 Policy: Buprenorphine Medical Policy No. 65 . 20 . 00.10 Last Updated 01 / 26 / 20 2 1 1 Medication Treatment Guidelines Disorders (SUDs) - Transmucosal Buprenorphine Medical p olicy n o. Julie Kmiec, DO. Assistant Professor of Psychiatry. University of Pittsburgh. kmiecj@upmc.edu. April 10, 2018. 1. Objectives. Review prevalence of opioid use disorders. Discuss the unmet needs for those with OUD. Therapy. Opioids. and HIV. You may know that…. Injection drug use (IDU), either directly or via sexual contact with an IDU partner, accounts for one-third of the cumulative estimated AIDS cases in the U.S.. Valerie . Carrejo. , MD FAAFP. Department of Family and Community Medicine. Resident School May 30, 2018. I have no disclosures. Objectives. By the end of this lecture, the learners will . Know about the UNMHS Urine Drug screen tip sheet. William J. Lorman, JD, PhD, MSN, PMHNP-BC, CARN-AP. V. P. & Chief Clinical Officer, Livengrin Foundation, Inc.. Ass’t. Clinical Professor, Doctoral Nursing Dept., . Drexel University. wlorman@livengrin.org.